Funding-University of
Kentucky/Novo Nordisk Diabetes and Obesity Biologics Science; February 7, 2014
Sent
on behalf of Taunya Phillips Walker, Assistant VP – UK Commercialization &
Economic Development
NOVO
NORDISK RESEARCH FUNDING OPPORTUNITY
Novo
Nordisk has invited University of Kentucky faculty members, (along with those
from other select mid-Atlantic academic and medical research institutions) who
could have novel ideas for biologics innovation within diabetes and obesity
research, to participate in the Novo Nordisk Diabetes and Obesity Biologics
Science Forum.
The
areas of research in the scope of the Science Forum program are: Non-clinical
research related to new biologic therapeutics and targets amenable to biologic
therapeutics or novel effects of known biologics in the field of Type 1
Diabetes and Type 2 Diabetes, including micro- and macro-vascular
complications, and obesity.
These
awards are designed to foster collaboration with Novo Nordisk R&D and to
facilitate translation of new ideas from early diabetes and obesity research
into innovation by bringing new biologics concepts to a pre-clinical Proof of
Principle milestone.
Types
of Awards
Early
Exploration
supports nonclinical research for early-stage hypotheses that do not yet have
(or only very limited) preliminary data, but show considerable promise for
advancing the treatment of diabetes or obesity. This includes target
discovery proposals. This award is $250,0001
for a 2-year period.
Proof
of Principle (PoP) supports nonclinical research for the
validation of early stage innovations with sufficient supporting data to
conclude on nonclinical PoP studies. This award is
$500,0001 for a 2-year period, and includes
the option to have additional scientific support provided by Novo Nordisk.
The
process is as follows:
1)
Submit a
2-page non-confidential summary by February 7, 2014 using the format provided
in the attached template from Novo Nordisk.
2)
Novo
Nordisk will select proposals for full in depth presentations by March 14,
2014.
3)
Present
full in-depth proposal at Science Forum in Washington, DC, April 1-2, 2014.
4)
Novo
Nordisk will decide which proposals to fund.
For
more information please contact:
Taunya
Phillips Walker
Associate
VP, Research Commercialization
University
of Kentucky
(859)
218-6509
Kristian
Tage Hansen, PhD
Senior
Director
Head
of Novo Nordisk Diabetes Innovation Outreach Program
+45
44434838 (direct)
+45
30754838 (mobile)
diabetesinnovation@novonordisk.com
1Direct research costs
only. In addition to funding of direct expenses, the Awards will cover
Institution’s standard indirect costs (F&A).